CSPC Pharma announced on September 20, 2024 that its developed valsartan amlodipine besylate tablets have been approved by the China National Medical Products Administration for clinical trials. This product is the world's first combined formulation of valsartan and amlodipine besylate that has been approved for clinical trials, and is suitable for the treatment of primary mild to moderate hypertension that cannot be controlled by monotherapy. Valsartan is an angiotensin II receptor antagonist, and amlodipine besylate is a calcium channel blocker. Both have extensive experience in combination therapy in clinical practice, and are expected to have clinical development value in terms of efficacy and safety.

CSPC Pharma announced on September 20, 2024 that its developed valsartan amlodipine besylate tablets have been approved by the China National Medical Products Administration for clinical trials. This product is the world's first combined formulation of valsartan and amlodipine besylate that has been approved for clinical trials, and is suitable for the treatment of primary mild to moderate hypertension that cannot be controlled by monotherapy. Valsartan is an angiotensin II receptor antagonist, and amlodipine besylate is a calcium channel blocker. Both have extensive experience in combination therapy in clinical practice, and are expected to have clinical development value in terms of efficacy and safety.